Brentuximab Vedotin

Pembrolizumab significantly improved PFS vs. brentuximab vedotin among patients with relapsed or refractory classical Hodgkin lymphoma, according to study results presented at the virtual European Hematology Association Annual Congress.

Pembrolizumab extended PFS compared with brentuximab vedotin for patients with relapsed or refractory classic Hodgkin lymphoma, according to study results presented during the ASCO20 Virtual Scientific Program.

Pembrolizumab significantly extended PFS compared with brentuximab vedotin among patients with relapsed or refractory classical Hodgkin lymphoma, according to randomized phase 3 study results released by the agent’s manufacturer.

In 2016, the FDA approved the first immunotherapy for lymphoma. Since then, the field has exploded and now, just 4 years later, there are nine FDA-approved immunotherapy options for lymphoma, according to the Cancer Research Institute.

Since the discovery of the CD30 molecule in 1982, progress has been made in the treatment and survival outcomes for patients with CD30-positive disease. Nearly 30 years after this discovery, brentuximab vedotin (Adcetris, Seattle Genetics), an antibody targeting CD30, was approved by the FDA.